Skip Navigation

Aba and Steroid Refractory cGVHD

A Potential New Approach to Treating Chronic Graft-Versus-Host Disease

Chronic graft-versus-host disease (cGVHD) remains a formidable challenge following allogeneic transplantation, impacting the quality of life of recipients and often unresponsive to conventional treatments. New approaches and treatments for cGVHD are desperately needed. A recent Phase II clinical trial evaluated the potential to use abatacept, a drug commonly used to treat rheumatoid arthritis, in managing steroid-refractory cGVHD. The findings provide some promise for transforming treatment approaches for this debilitating condition.

This clinical trial evaluated the potential to use Abatacept to treat cGVHD that does not respond to conventional therapy. The study included patients with steroid-refractory cGVHD, a condition marked by persistent symptoms despite ongoing treatment. These patients spanned in age from 25-77 years old and had received a BMT for acute myeloid leukemia, myelodysplastic syndrome, non-Hodgkin's lymphoma, or other disease.

The trial's findings offer some potential hope for patients with steroid refractory cGVHD. Among the 39 patients evaluated, 58% achieved an overall partial response, with significant improvement seen in impacted organs like the lungs, liver, gastrointestinal tract, and mouth. Even patients with cGVHD progression in certain organs exhibited a resp onse in others following treatment with abatacept. Use of abatacept also led to a reduction in overall use of corticosteroids, an effect that holds great promise in alleviating the long-term side effects associated with these medications.

While the study's outcomes are undoubtedly promising, they are just the beginning. Abatacept's approval for acute GVHD prophylaxis, coupled with its novel immunomodulatory role, ignites fresh avenues for treating cGVHD. As researchers delve deeper, the focus will shift to deciphering biomarkers predictive of response, defining optimal combinations with existing therapies, and embracing a patient-centered approach to revolutionize cGVHD management.

This phase II study casts a hopeful spotlight on the complex landscape of cGVHD treatment. As medical science advances and collaborations flourish, the journey towards conquering cGVHD takes a crucial step forward, bringing renewed hope to countless lives.

Learn more by reviewing a comprehensive analysis and description of the study.

View Infographic